Skip to content
Triangle logo TriangleGet started
← Study library

NCT00721513 · REGISTRY CONDITION SEARCH

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2020-04-07

RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with cetuximab and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel, cisplatin, and fluorouracil together with cetuximab and radiation therapy works in treating patients with locally advanced head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Objective Response Rate

→

outcome · POSTED

Best Overall Response Rate

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Participants With Distant Metastasis

→

outcome · POSTED

Quality of Life - Functional Assessment of Cancer Therapy - General (FACT-G)

→

outcome · POSTED

Number of Participants With Local-Regional Control

→

outcome · POSTED

Performance Status Scale for Head and Neck Cancer

→

outcome · POSTED

MD Anderson Dysphagia Inventory

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion: * Histologically confirmed (from primary lesion and/or lymph nodes) squamous cell carcinoma (SCC) of the head and neck, including the following subtypes: * Oropharynx * Hypopharynx * Larynx * Primary site of tumor must not include any of the following: * Nasopharynx * Sinuses * Salivary glands * Stage III or IV disease that is unresectable (oropharynx, larynx, or hypopharynx) OR that is resectable with organ-sparing goal (oropharynx or hypopharynx) * Measurable disease by CT scan or MRI * No definitive evidence of distant metastasis * ECOG performance status 0-1 * ANC ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Hemoglobin ≥ 8 g/dL * Total bilirubin ≤ normal * Except in the case where the elevated total bilirubin is not a sign of liver disease (i.e., Gilbert syndrome), in which case a total bilirubin ≤ 2 times upper limit of normal (ULN) is allowed provided direct bilirubin is ≤ ULN * AST, ALT, and alkaline phosphate (AP) meeting the following criteria: * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST or ALT normal * Creatinine ≤ 1.5 mg/dL * Negative pregnancy test (for women of childbearing potential) * Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment * Willing to undergo laryngoscopy with biopsy of residual tumor at primary site (as part of a comprehensive evaluation of tumor response after completion of the induction chemotherapy portion of study treatment) Exclusion: * History of severe hypersensitivity reaction to docetaxel or to other drugs formulated with polysorbate 80 * Other invasive malignancy within the past 3 years, except nonmelanoma skin cancer * Prior allergic reaction to the study drug(s) * Concurrent uncontrolled illness including, but not limited to, any of the following: * Ongoing or active infection * Psychiatric illness/social situation that would limit compliance with study requirements * Significant history of uncontrolled cardiac disease, including any of the following: * Uncontrolled hypertension * Unstable angina * Myocardial infarction within the past 6 months * Uncontrolled congestive heart failure * Cardiomyopathy with decreased left ventricular ejection fraction (i.e., LVEF \< 45%) * Uncontrolled condition that, in the opinion of the investigator, would interfere in the safe and timely completion of study procedures * History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest CT scan * HIV positivity * Pregnant or nursing * Prior chemotherapy for the study cancer * Prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields * Prior chemotherapy, biological therapy, or hormone therapy within the last one year * Prior initial surgical treatment, except diagnostic biopsy of the primary site or nodal sampling of neck disease * Prior radical or modified neck dissection * Prior therapy that specifically and directly targets the EGFR pathway * Concurrent investigational agents
healthy Volunteers
false
maximum Age
120 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy
    intervention Names
    1. Biological: cetuximab
    2. Drug: cisplatin
    3. Drug: docetaxel
    4. Drug: fluorouracil
    5. Procedure: computed tomography
    6. Procedure: positron emission tomography
    7. Procedure: quality-of-life assessment
    8. Radiation: 3-dimensional conformal radiation therapy
    9. Radiation: intensity-modulated radiation therapy
    label
    TPFChemotherapy + Concomitant Cetuximab & RT
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    cetuximab
    type
    BIOLOGICAL
  2. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    cisplatin
    type
    DRUG
  3. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    docetaxel
    type
    DRUG
  4. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    fluorouracil
    type
    DRUG
  5. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    computed tomography
    type
    PROCEDURE
  6. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    positron emission tomography
    type
    PROCEDURE
  7. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    quality-of-life assessment
    type
    PROCEDURE
  8. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    3-dimensional conformal radiation therapy
    type
    RADIATION
  9. arm Group Labels
    1. TPFChemotherapy + Concomitant Cetuximab & RT
    name
    intensity-modulated radiation therapy
    type
    RADIATION
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
20
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Progression-free Survival
    time Frame
    up to 2 years
secondary Outcomes
  1. description
    Will be measured by CT scan /MRI of the head and neck with corroborative results of direct biopsy of any residual tumor at primary site.
    measure
    Objective Response Rate
    time Frame
    up to 2 years
  2. description
    Defined as rate of complete and partial responses (at least 30% decrease in the sum of the longest diameter of target lesions), measured by CT scan or MRI of the head and neck after completion of multimodality treatment with induction TPF (Docetaxel, cisplatin and fluorouracil) chemotherapy followed by combined ERT. We will use RECIST (Response Evaluation Criteria In Solid Tumors) (Therasse et al, 2000) for evaluation of response.
    measure
    Best Overall Response Rate
    time Frame
    up to 2 years
  3. measure
    Overall Survival
    time Frame
    up to 2 years
  4. measure
    Number of Participants With Distant Metastasis
    time Frame
    up to 2 years
  5. description
    Four subscales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). Items are rated on a five-point scale: 0-"not at all", 1- "a little bit", 2-"somewhat", 3- "quite a bit" and 4-"very much". Overall quality of life is the sum of the core items of the FACT-G possible range of 0-108 points. The higher the score the better the quality life. This interval includes 0, we will conclude that there is not conclusive statistical evidence that there is an improvement or worsening. If the interval does not include 0 we can determine whether there was a significant improvement (or worsening) depending on which side of the 0 the interval is on. The total outcome index score (possible range 0-108 points) is the sum of the physical and functional well being and additional concerns categories from the FACT-G.
    measure
    Quality of Life - Functional Assessment of Cancer Therapy - General (FACT-G)
    time Frame
    Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years
  6. measure
    Number of Participants With Local-Regional Control
    time Frame
    up to 2 years
  7. description
    Consists of assessment of three functions (subscales): Normalcy of diet, eating in public, and understandability of speech. The interviewer rates the patient on each scale based on the patient's responses to targeted questions. Scores range from 0-100 (Full performance (100 score), moderate or severe impairment (≤ 50 score)). The higher the score, the better the ability of the patient to function.
    measure
    Performance Status Scale for Head and Neck Cancer
    time Frame
    Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years
  8. description
    The MD Anderson Dysphasia Inventory (MDADI) is a survey specifically designed to assess dysphasia. It contains 20 questions directly addressing the swallowing function and several other general questions. The questionnaire asks for participants views about their swallowing ability at baseline, pre-radiation therapy and post-radiation therapy. All questions except for E7 and F2: Strongly Agree = 1 point, Agree = 2 points, No Opinion = 3 points, Disagree = 4 points, Strongly Disagree. E7 and F2: Strongly agree = 5 points, Agree = 4 points, no opinion = 3 points, disagree = 2 points, strongly disagree = 1 point. Scores range from 20 (extremely low-functioning) to 100 (high-functioning).
    measure
    MD Anderson Dysphagia Inventory
    time Frame
    Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with cetuximab and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel, cisplatin, and fluorouracil together with cetuximab and radiation therapy works in treating patients with locally advanced head and neck cancer.
detailed Description
OBJECTIVES: Primary * Evaluate the progression-free survival of patients with locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil followed by concurrent cetuximab and radiotherapy. Secondary * Assess the objective response rate in patients treated with this regimen. * Assess the best overall response rate, overall survival, local-regional control, and distant failure in patients treated with this regimen. * Assess the acute and long-term toxicity associated with this regimen in these patients. * Assess quality of life and swallowing in patients treated with this regimen. * Determine the accuracy of PET/CT scan in evaluating objective response; in detecting residual disease at primary sites and nodes; in guiding the recommendation for salvage surgery or for neck dissection; and in early detection of recurrent or metastatic disease. OUTLINE: Patients are stratified according to nodal status (N2b-c or N3 vs N0-2a), tumor characteristics of invasiveness (present vs absent), human papilloma virus (HPV) status (positive vs negative), and primary tumor site (hypopharynx vs larynx vs oropharynx). Patients receive induction chemotherapy comprising docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks after completion of induction chemotherapy, patients receive cetuximab IV once weekly for 7 weeks. Beginning 1 week after the first dose of cetuximab, patients undergo concurrent intensity-modulated radiotherapy or conventional 3-dimensional radiotherapy once or twice daily 5-6 days a week for up to 6 weeks. Patients with persistent disease undergo salvage resection of the primary tumor and/or neck dissection approximately 3 months after the completion of radiotherapy. Patients undergo quality of life and swallowing evaluations periodically. Patients undergo PET/CT scan at baseline, before beginning radiotherapy, at 6-8 weeks after completion of study treatment, every 6 months for 5 years, and then annually thereafter. After completion of study treatment, patients are followed at 4 and 8 weeks, every 2 months for 2 years, every 3 months for 1 year, and then every 6 months thereafter.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6762b11b9706fa25cb2a
      requested nct id
      NCT00721513
      primary nct id
      NCT00721513
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      a7b333ea8266e64e5afe56584061737435be073639261518c6833ca5532dd409
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6762b11b9706fa25cb2a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00721513
      occurrences
      1. context exact
        NCT00721513
        end
        11
        exact text
        NCT00721513
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6aa42b817ff37703041e00780dc96e2369a3666211eafd60b3df417802f96711
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-bec4b39dd1a3acd6cc35
      requested nct id
      NCT00721513
      primary nct id
      NCT00721513
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      6e85fad051f6f48530c579aa5f5722c656b4c470704fe12036325f68a24f0281
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-bec4b39dd1a3acd6cc35
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00721513
      occurrences
      1. context exact
        NCT00721513
        end
        11
        exact text
        NCT00721513
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/0/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6aa42b817ff37703041e00780dc96e2369a3666211eafd60b3df417802f96711

    Preserved source evidence · Not medical advice